First Use of Combination Oral Deucravacitinib With Tapinarof Cream for Treatment of Severe Plaque Psoriasis.
J Drugs Dermatol
; 23(3): 192-194, 2024 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-38443116
ABSTRACT
Plaque psoriasis is a chronic, immune-mediated, cutaneous, and systemic inflammatory dermatosis. Its pathogenesis involves the dysregulation of the interleukin (IL)-23/IL-17 signaling pathway. There are a range of treatment options available, encompassing topical agents, biologics, oral systemic therapy, and phototherapy. The utility of combination treatment has also been described and is a budding field of research. Here we describe the first case of adult severe generalized plaque psoriasis treated with once-daily oral deucravacitinib 6 mg combined with tapinarof cream 1% applied once daily. To our knowledge, the combination of these agents has not yet been described in the literature. J Drugs Dermatol. 2024;23(3) doi10.36849/JDD.8091.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Estilbenos
/
Compostos Heterocíclicos
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article